Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 650 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR Talking About Sexual Health Concerns With Your Cancer Care Team: How... September 29, 2022 Uncle Charlie’s Promise February 23, 2021 Mom Diagnosed With Stage III Breast Cancer While Nursing Her 9-Month-Old... May 20, 2020 Enhertu Improves Survival for Metastatic “HER2-Low” Breast Cancer July 5, 2022 Load more HOT NEWS Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical... ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to... 2020 National Cancer Opinion Survey: Cancer Screening and Mental Health During... Airline Won’t Let Dad And Newborn On Plane, So Kind Stranger...
